COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial
Cédric Annweiler
(1, 2)
,
Mélinda Beaudenon
(3, 2)
,
Jennifer Gautier
(3, 2)
,
Romain Simon
(3, 2)
,
Vincent Dubée
(4, 5, 2)
,
Justine Gonsard
(2)
,
Elsa Parot-Schinkel
(3, 2)
,
Amal Aidoud
(6, 2)
,
Guillaume Albaret
(7, 8, 2)
,
Cédric Annweiler
(1, 2)
,
Alexandra Audemard-Verger
(9, 2)
,
Marine Asfar
(3, 2)
,
Jean Barré
(10, 2)
,
Florian Berteau
(11, 2)
,
Gaëlle Bertoletti
(2)
,
Jean-Baptiste Beuscart
(12, 2)
,
Adrien Bigot
(6, 2)
,
Sophie Boucher
(13, 3, 14, 2)
,
Elisabeth Botelho-Nevers
(15, 2)
,
Isabelle Bourdel-Marchasson
(16, 2)
,
Anne Sophie Boureau
(2)
,
Antoine Brangier
(1, 2)
,
Céline Brouessard
(2)
,
Marie Laure Bureau
(2)
,
Noëlle Cardinaud
(17, 2)
,
Michel Carles
(18, 19, 20, 2)
,
Karine Castro-Lionard
(2)
,
Thomas Celarier
(21, 2)
,
Guillaume Chapelet
(14, 2)
,
David Chirio
(22, 2)
,
Emilie Clabé
(23, 2)
,
Philippe Codron
(24, 2)
,
Johan Courjon
(20, 2)
,
Éric Cua
(22, 2)
,
Marie Danet-Lamasou
(25, 2)
,
Alexiane Decorbez
(26, 2)
,
Marine de la Chapelle
(2)
,
Elisa Demonchy
(26, 2)
,
Edouard Desvaux
(2)
,
Monique D’hautefeuille
(2)
,
Vincent Dubée
(4, 5, 2)
,
Guillaume Duval
(2)
,
Bertrand Fougère
(2)
,
Paul Gassie
(2)
,
Nicolas Giroult
(2)
,
Olivier Guérin
(2)
,
Régis Hankard
(2)
,
Marjorie Houvet
(2)
,
Stéphanie Jobard
(2)
,
Carole Lacout
(2)
,
Aurélie Lafargue
(2)
,
Cécile Laubarie-Mouret
(2)
,
Maxime Le Floch
(2)
,
Sylvain Le Gentil
(2)
,
Sébastien Lléonart
(2)
,
Jocelyne Loison
(2)
,
Rafaël Mahieu
(2)
,
François Maillot
(2)
,
Laure Martinez
(2)
,
Marie Mathieu
(2)
,
Anthony Mauclere
(2)
,
Pierre Ménager
(2)
,
Emeline Michel
(2)
,
Thai Binh Nguyen
(2)
,
Romain Ordonez
(2)
,
Marie Otekpo
(2)
,
Virginie Pichon
(2)
,
Fanny Poitau
(2)
,
Gary Pommier
(2)
,
Valérie Rabier
(2)
,
Karine Risso
(2)
,
Hélène Rivière
(2)
,
Agnès Rouaud
(2)
,
Claire Roubaud-Baudron
(2)
,
Guillaume Sacco
(2)
,
Frédéric Scholastique
(2)
,
Etienne Seronie-Doutriaux
(2)
,
Achille Tchalla
(2)
,
Wojciech Trzepizur
(2)
,
Yves-Marie Vandamme
(2)
1
LPPL -
Laboratoire de Psychologie des Pays de la Loire
2 COVIT-TRIAL study group
3 CHU Angers - Centre Hospitalier Universitaire d'Angers
4 CHU Saint-Antoine [AP-HP]
5 SU - Sorbonne Université
6 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
7 Pôle de Gérontologie Clinique
8 BaRITOn - Bordeaux Research In Translational Oncology [Bordeaux]
9 Service de médecine interne [CHU Caen]
10 Lattice - Lattice - Langues, Textes, Traitements informatiques, Cognition - UMR 8094
11 CHU - BREST - Hôpital de la Cavale Blanche - CHRU Brest
12 METRICS - Evaluation des technologies de santé et des pratiques médicales - ULR 2694
13 ED 515 - Complexité du vivant
14 UA - Université d'Angers
15 GIMAP - Groupe Immunité des Muqueuses et Agents Pathogènes
16 BPH - Bordeaux population health
17 CHU Limoges
18 CHU Pointe-à-Pitre / Abymes [Guadeloupe]
19 UA - Université des Antilles
20 C3M - Centre méditerranéen de médecine moléculaire
21 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
22 Service d'infectiologie [CHU Nice]
23 UB - Université de Bordeaux
24 MITOVASC - MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale
25 CRMSB - Centre de résonance magnétique des systèmes biologiques
26 UNS UFR Médecine - Université Nice Sophia Antipolis - Faculté de Médecine
2 COVIT-TRIAL study group
3 CHU Angers - Centre Hospitalier Universitaire d'Angers
4 CHU Saint-Antoine [AP-HP]
5 SU - Sorbonne Université
6 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
7 Pôle de Gérontologie Clinique
8 BaRITOn - Bordeaux Research In Translational Oncology [Bordeaux]
9 Service de médecine interne [CHU Caen]
10 Lattice - Lattice - Langues, Textes, Traitements informatiques, Cognition - UMR 8094
11 CHU - BREST - Hôpital de la Cavale Blanche - CHRU Brest
12 METRICS - Evaluation des technologies de santé et des pratiques médicales - ULR 2694
13 ED 515 - Complexité du vivant
14 UA - Université d'Angers
15 GIMAP - Groupe Immunité des Muqueuses et Agents Pathogènes
16 BPH - Bordeaux population health
17 CHU Limoges
18 CHU Pointe-à-Pitre / Abymes [Guadeloupe]
19 UA - Université des Antilles
20 C3M - Centre méditerranéen de médecine moléculaire
21 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
22 Service d'infectiologie [CHU Nice]
23 UB - Université de Bordeaux
24 MITOVASC - MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale
25 CRMSB - Centre de résonance magnétique des systèmes biologiques
26 UNS UFR Médecine - Université Nice Sophia Antipolis - Faculté de Médecine
Cédric Annweiler
- Fonction : Auteur
- PersonId : 1024384
- ORCID : 0000-0002-7199-8109
- IdRef : 147568560
Jennifer Gautier
- Fonction : Auteur
Vincent Dubée
- Fonction : Auteur
Elisabeth Botelho-Nevers
- Fonction : Auteur
- PersonId : 1452409
- IdHAL : ebotelhonevers
- ORCID : 0000-0003-2773-7750
- IdRef : 128018674
Johan Courjon
- Fonction : Auteur
Vincent Dubée
- Fonction : Auteur
Bertrand Fougère
- Fonction : Auteur
- PersonId : 745031
- IdHAL : bertrand-fougere
- ORCID : 0000-0002-4809-3547
- IdRef : 140413073
Résumé
Abstract Background With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on the immediate repurposing of existing drugs gives hope of curbing the COVID-19 pandemic. A recent unbiased genomics-guided tracing of the SARS-CoV-2 targets in human cells identified vitamin D among the three top-scoring molecules manifesting potential infection mitigation patterns. Growing pre-clinical and epidemiological observational data support this assumption. We hypothesized that vitamin D supplementation may improve the prognosis of COVID-19. The aim of this trial is to compare the effect of a single oral high dose of cholecalciferol versus a single oral standard dose on all-cause 14-day mortality rate in COVID-19 older adults at higher risk of worsening. Methods The COVIT-TRIAL study is an open-label, multicenter, randomized controlled superiority trial. Patients aged ≥ 65 years with COVID-19 (diagnosed within the preceding 3 days with RT-PCR and/or chest CT scan) and at least one worsening risk factor at the time of inclusion (i.e., age ≥ 75 years, or SpO2 ≤ 94% in room air, or PaO2/FiO2 ≤ 300 mmHg), having no contraindications to vitamin D supplementation, and having received no vitamin D supplementation > 800 IU/day during the preceding month are recruited. Participants are randomized either to high-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion) or to standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion). Two hundred sixty participants are recruited and followed up for 28 days. The primary outcome measure is all-cause mortality within 14 days of inclusion. Secondary outcomes are the score changes on the World Health Organization Ordinal Scale for Clinical Improvement (OSCI) scale for COVID-19, and the between-group comparison of safety. These outcomes are assessed at baseline, day 14, and day 28, together with the serum concentrations of 25(OH)D, creatinine, calcium, and albumin at baseline and day 7. Discussion COVIT-TRIAL is to our knowledge the first randomized controlled trial testing the effect of vitamin D supplementation on the prognosis of COVID-19 in high-risk older patients. High-dose vitamin D supplementation may be an effective, well-tolerated, and easily and immediately accessible treatment for COVID-19, the incidence of which increases dramatically and for which there are currently no scientifically validated treatments. Trial registration ClinicalTrials.gov NCT04344041 . Registered on 14 April 2020 Trial status Recruiting. Recruitment is expected to be completed in April 2021.
| Origine | Publication financée par une institution |
|---|---|
| licence |
